Curis Issues Clarification to Article by CBS.MarketWatch.com.Business/Science Editors CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 14, 2001 Curis, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CRIS) today announced that on Friday, August 10, 2001, Curis filed with the Securities and Exchange Commission (the "SEC") post-effective amendment no. 1 converting a registration statement on Form S-1 to a more efficient and shorter Form S-3. The registration statement on Form S-1 originally had been filed in connection with the PIPE financing completed by Curis in December 2000. In both the Form S-1 and S-3 registration statement Curis was required to include a table stating how many shares the participants in the PIPE financing were able to sell under the registration statement. While this list identifies shareholders who could sell under the registration statement, these shareholders are not necessarily selling at this time. "The filing by Curis of post-effective amendment no. 1 on Form S-3 does not communicate any change in intention by the participants in the PIPE to sell their shares," said George Eldridge, vice president and chief financial officer. "Now that Curis has been trading for over a year, Curis is allowed to convert its registration statement on Form S-1 to a Form S-3 format. It was a filing done by us simply for future convenience and cost savings. CBS (Cell Broadcast Service) See cell broadcast. .MarketWatch.com was incorrect in its interpretation that the amended registration statement filed on Form S-3 indicated an intention by any of the PIPE participants to sell their Curis shares and this fact was communicated to CBS.MarketWatch.com yesterday." About Curis, Inc. Curis, Inc. is developing products based on technologies in the emerging field of regenerative re·gen·er·a·tive adj. 1. Of, relating to, or marked by regeneration. 2. Tending to regenerate. re·gen medicine. The Company is combining insights gained through the study of developmental biology Developmental biology A large field of investigation that includes the study of all changes associated with an organism as it progresses through the life cycle. The life cycles of all multicellular organisms exhibit many similarities. with high-throughput screening High-throughput screening (HTS), is a method for scientific experimentation especially used in drug discovery and relevant to the fields of biology and chemistry. Purpose and method capabilities, proteins, cells and biocompatible materials biocompatible material, n a substance that does not threaten, impede, or adversely affect living tissue. to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site and view our webcast productions on Monday, August 13, 2001 at www.curis.com. The statements in this news release that are not historical facts are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis Annual Report on Form 10-k Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31,2000 with the Securities and Exchange Commission on March 30, 2001. The forward-looking statements contained herein represent the judgment of Curis, as of the date of this release, and Curis disclaims any intent or obligation to update such forward-looking statements to reflect any change in Curis' expectations with regard thereto or any change in events, conditions, circumstances on which such statements are based. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion